Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | DGKA | P23743 | 1/20 | 0.52 |
| ▸ | PAM | P19021 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.44 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.44 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27558150 | 1.00 | MAPT (0.53) | MAPTDGKAPAMLMNAKDM4E | |
| SCHEMBL29761219 | 1.00 | MAPT (0.53) | MAPTDGKAPAMLMNAKDM4E | |
| SCHEMBL27805190 | 1.00 | MAPT (0.53) | MAPTDGKAPAMLMNAKDM4E | |
| SCHEMBL11021553 | 0.98 | MAPT (0.51) | MAPTDGKAPAMLMNAKDM4E | |
| SCHEMBL27814847 | 0.93 | MAPT (0.43) | MAPTDGKAPAMLMNAKDM4E | |
| SCHEMBL1488916 | 0.93 | MAPT (0.59) | MAPTDGKAPAMLMNAKDM4E | |
| SCHEMBL4933827 | 0.93 | MAPT (0.59) | MAPTDGKAPAMLMNAKDM4E | |
| SCHEMBL65558 | 0.93 | MAPT (0.59) | MAPTDGKAPAMLMNAKDM4E | |
| SCHEMBL27537619 | 0.93 | MAPT (0.59) | MAPTDGKAPAMLMNAKDM4E | |
| SCHEMBL30064439 | 0.91 | MAPT (0.58) | MAPTDGKAPAMLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115926147-A | Preparation method of modified nylon material containing talcum powder | 苏州优矿塑新材料股份有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-110951245-A | Preparation method of double-stearoyl sodium tartrate diester modified talcum powder and nylon composite material | 三菱电机(中国)有限公司 | 2020-04-03 | — | — | CN | claimed |
| CN-105594972-A | Gum capable of controllably releasing resveratrol and preparing method thereof | CHONGQING ACAD OF SCIENCE & TECH | 2016-05-25 | — | — | CN | claimed |
| US-20100034925-A1 | Pet Food and Processes of Producing the Same | NESTEC S.A. (CH) | 2010-02-11 | — | — | US | claimed |
| CN-101442912-A | Pet food and preparation method thereof | NESTEC SA (CH) | 2009-05-27 | — | — | CN | claimed |
| EP-1983841-A1 | PET FOOD AND PROCESSES OF PRODUCING THE SAME | NESTEC S.A. (CH) | 2008-10-29 | — | — | EP | claimed |
| WO-2007073903-A1 | PET FOOD AND PROCESSES OF PRODUCING THE SAME | NESTEC S.A. (CH) | 2007-07-05 | — | — | WO | claimed |
| EP-1800545-A1 | Pet food and processes of producing the same | NESTEC S.A. (CH) | 2007-06-27 | — | — | EP | claimed |
| US-20040023935-A1 | Inhalation compositions, methods of use thereof, and process for preparation of same | DEY, L.P. | 2004-02-05 | — | — | US | claimed |
| EP-4687886-A1 | METHODS OF DOSING SPINOGENIC COMPOUNDS | Spinogenix, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4665322-A1 | DYSREGULATION OF PLANKTONIC BACTERIAL METABOLISM | Neolixir Limited (AU) | 2025-12-24 | — | — | EP | disclosed |
| US-12370352-B2 | Nasal and ophthalmic delivery of aqueous corticosteroid solutions | CYDEX PHARMACEUTICALS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240423962-A1 | FASCIN BINDING COMPOUNDS FOR SPINOGENESIS | SPINOGENIX INC (US) | 2024-12-26 | — | — | US | disclosed |
| US-20240397944-A1 | METHODS FOR BIOFILM DISRUPTION | Lixa Limited (AU) | 2024-12-05 | — | — | US | disclosed |
| US-20030055026-A1 | Intended for administration as a nebulized aerosol; for therapy and prophylaxis symptoms of bronchocon-strictive disorders | DEY L.P. | 2003-03-20 | — | — | US | disclosed |
| US-20020183293-A1 | Administering durg comprising formoterol, or a derivative thereof and asteroidal anti-inflammatory agent, or a derivative in a pharmacologically suitable fluid, wherein the drug formulation is stable during long term storage | MYLAN PHARMACEUTICALS, INC. | 2002-12-05 | — | — | US | disclosed |
| WO-2002083113-A2 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL AND A STEROID SUCH AS E.G. BUDESONIDE OR FLUTICASONE FOR DELIVERY INTO THE LUNGS VIA NEBULIZATION | DEY, L.P. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-6235067-B1 | LIQUID HYDROCARBON FUEL AND WATER SUPERCRITICAL MIXTURE EMITTER NOZZLES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2001-05-22 | — | — | US | disclosed |
| EP-0799837-A2 | Aqueous compositions comprising amylopectin-potatostarch and process for their manufacture | Coöperatieve Verkoop- en Productievereniging van Aardappelmeel en Derivaten 'AVEBE' B.A. (NL) | 1997-10-08 | — | — | EP | disclosed |
| US-4411813-A | Process for emulsifying and stabilizing anise essences, anethole and essential oils or fats in the aqueous phase | VOISIN MAX (FR) | 1983-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023935-A1 | Inhalation compositions, methods of use thereof, and process for preparation of same | IL5, CHRM3, NOX5 | MAPT 2021/4885DGKA 2620/4885PAM 214/4885 |
| US-20240423962-A1 | FASCIN BINDING COMPOUNDS FOR SPINOGENESIS | FSCN1, SMN1; SMN2, DCX | MAPT 410/4885DGKA 4097/4885PAM 4609/4885 |
| US-12370352-B2 | Nasal and ophthalmic delivery of aqueous corticosteroid solutions | CRH, HRH1, IL5 | MAPT 1791/4885DGKA 3420/4885PAM 2744/4885 |
| US-20240397944-A1 | METHODS FOR BIOFILM DISRUPTION | FGB, MMP8, HAO2 | MAPT 4462/4885DGKA 2026/4885PAM 1324/4885 |
| US-20030055026-A1 | Intended for administration as a nebulized aerosol; for therapy and prophylaxis symptoms of bronchocon-strictive disorders | SERPINA6, CALU, TSLP | MAPT 1393/4885DGKA 4429/4885PAM 2350/4885 |
| US-20020183293-A1 | Administering durg comprising formoterol, or a derivative thereof and asteroidal anti-inflammatory agent, or a derivative in a pharmacologically suitable fluid, wherein the drug formulation is stable during long term storage | AREG, IL5, IL17A | MAPT 49/4885DGKA 1228/4885PAM 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.